公开(公告)号：US20240139336A1

公开(公告)日：2024-05-02

申请号：US18296642

申请日：2023-04-06

申请人： The Regents of the University of Michigan

发明人： Yu Lei ,  Yee Sun Tan ,  Kanokwan Sansanaphongpricha ,  Duxin Sun ,  Hongwei Chen ,  Hongxiang Hu

IPC分类号： A61K47/69 ,  A61K39/00 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/64 ,  A61P35/00

CPC分类号： A61K47/6929 ,  A61K39/0003 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61K47/6923 ,  A61P35/00 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/60 ,  A61K2039/622 ,  B82Y5/00

摘要： The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

公开(公告)号：US11701433B2

公开(公告)日：2023-07-18

申请号：US16619802

申请日：2018-06-01

申请人： The Regents of the University of Michigan

发明人： Yu Lei ,  Yee Sun Tan ,  Kanokwan Sansanaphongpricha ,  Duxin Sun ,  Hongwei Chen ,  Hongxiang Hu

IPC分类号： A61K9/00 ,  A61K47/69 ,  A61K47/64 ,  A61P35/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  B82Y5/00

CPC分类号： A61K47/6929 ,  A61K39/0003 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61K47/6923 ,  A61P35/00 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/60 ,  A61K2039/622 ,  B82Y5/00

摘要： The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

公开(公告)号：US20240226104A1

公开(公告)日：2024-07-11

申请号：US18556250

申请日：2022-04-20

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Wei Gao ,  Duxin Sun ,  Fei Wen ,  Ruiting Li ,  Hongxiang Hu ,  Luke F. Bugada ,  Yudong Song ,  Mahamadou Djibo

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K9/51 ,  A61K31/337 ,  A61P35/04

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K9/5169 ,  A61K31/337 ,  A61P35/04

摘要： The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.

公开(公告)号：US20230183282A1

公开(公告)日：2023-06-15

申请号：US17995254

申请日：2021-04-01

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Duxin Sun ,  Wei Gao ,  Hongxiang Hu ,  Mohamed Dit Mady Traore ,  Yudong Song ,  Bo Wen ,  Miao He ,  Hebao Yuan ,  Ruiting Li

IPC分类号： C07H7/06 ,  A61P31/12 ,  A61K9/127 ,  A61K9/51

CPC分类号： C07H7/06 ,  A61P31/12 ,  A61K9/127 ,  A61K9/5169

摘要： The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).

公开(公告)号：US20230025865A1

公开(公告)日：2023-01-26

申请号：US17784404

申请日：2020-12-11

申请人： The Regents of the University of Michigan

发明人： Duxin Sun ,  Wei Gao ,  Hongxiang Hu

IPC分类号： C07D401/14 ,  A61K9/14 ,  A61P35/00

摘要： This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.